ctDNA Testing to Inform Standard-of-Care Treatment Decisions in People With Endometrial Cancer

The researchers are doing this study to evaluate the use of circulating tumor DNA (ctDNA) testing in making treatment decisions for advanced/recurrent endometrial cancer that has a change (mutation) in the mismatch repair deficient (MMR-D) gene or microsatellite instability high (MSI-H) gene. The researchers will see how doctors and their patients use the results of ctDNA testing after 1 year of standard chemotherapy and immune checkpoint inhibitor (ICI) treatment to decide whether to continue maintenance ICI treatment past 1 year. The researchers will also look at the health outcomes of peopl

Trial Details

NCT ID
NCT07270666
Phase
NA
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • ctDNA Testing
  • Blood draw
  • Surveys
  • Semi-structured interviews
Locations (sample)
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Montvale, New Jersey, United States|41.04676,-74.02292
  • Commack, New York, United States|40.84288,-73.29289
  • Harrison, New York, United States|40.96899,-73.71263

Key Eligibility Criteria

  • Patients must have pathologically confirmed endometrial cancer
  • Patients with advanced endometrial cancer
  • Stage III with residual disease
  • °Select patients with Stage III disease and no residual disease can be enrolled after discussion with PI

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →